GX-1 ( Ariflex )
GX-1 (Ariflex) is built on Endurion’s LogicGate™ cellular programming technology,
A next-generation programmable cell and gene therapy
GX-1 (Ariflex) is Endurion’s lead investigational cell and gene therapy program, designed to deliver precise, programmable therapeutic responses for complex diseases with high unmet medical need. Developed using Endurion’s proprietary LogicGate™ platform, GX-1 (Ariflex) represents a next-generation approach to cell engineering—combining biological intelligence with advanced genetic control.
- Engineered with LogicGate™ technology to deliver controlled, signal-dependent therapeutic responses.
- Multi-input cellular logic enhances specificity while minimizing off-target activity.
- Automated, modular production enables consistent quality from clinical development to commercialization.
Built on advanced genetic control and systems biology
GX-1 (Ariflex) is engineered to function as an intelligent therapeutic system, capable of sensing defined biological signals and responding with targeted therapeutic action.
Scientific Rationale
GX-1 (Ariflex) is designed as an intelligent therapeutic system that responds to defined biological signals. By enabling controlled activation and targeted function, the therapy aims to improve specificity, durability, and overall therapeutic performance.
Platform & Technology
Built on Endurion’s proprietary LogicGate™ platform, GX-1 (Ariflex) utilizes programmable genetic circuits to precisely regulate cellular behavior. This modular design allows for adaptable optimization and future expansion across multiple indications.
Manufacturing & Scalability
GX-1 (Ariflex) is supported by an automated, modular manufacturing process designed to ensure reproducibility, scalability, and cost efficiency. This approach enables consistent product quality from early clinical development through potential commercialization.
Development Status
GX-1 (Ariflex) is currently in clinical-stage development. The program is progressing through rigorous scientific and regulatory evaluation, with a focus on safety,
performance, and translational impact.
Engineered cells that respond with precision and control
GX-1 (Ariflex) is designed using advanced cellular engineering to enable precise, programmable responses to specific biological signals. Rather than remaining continuously active, the engineered cells are programmed to sense defined inputs within the disease environment and activate only when required. This controlled behavior is intended to improve therapeutic accuracy, enhance safety, and reduce unintended effects, delivering a more refined and intelligent treatment approach.
Quality Assurance
Excellent support
Programmable therapeutic control
GX-1 (Ariflex) uses advanced genetic programming to enable cells to sense defined biological signals and activate only when needed, delivering targeted and controlled therapeutic responses.
Signal-driven therapeutic activation
The engineered cells respond dynamically to their environment, allowing for improved specificity, reduced off-target activity, and enhanced functional performance.
Designed with control at every level
Multi-input cellular logic supports refined regulation of cell behavior, aiming to improve safety, durability, and consistency across clinical applications.